Pérez Martín Jesús
Rev Alerg Mex. 2006 Nov-Dec;53(6):195-200.
Allergic rhinitis is a very frequent inflammatory disease of nasal mucosa that warranties its symptomatic treatment.
To evaluate the therapeutic effect of the mequitazine in the treatment of patient with allergic rhinitis and conjunctivitis symptoms, the grade of the physician and patient satisfaction, as well as the quality of life and the side effects of the treatment.
Clinical multicentric, open, longitudinal study made in the Mexican Republic with patients from 3 to 18 years of age and 113 doctors. All the patients were carried out a clinical evaluation, registration of the intensity of the symptoms and signs and the affectation in their daily activities. The diagnosis of allergic rhinitis and conjunctivitis settled down with base on the data of the clinical history and the exploration. All the patients were prescribed mequitazine. To those of 3 to 5 years of age: 7.5 mL a day, to those of 6 to 12 years: 10 mL, and to those of 12 to 18 years a pill of 10 mg a day.
374 patients were studied: 44.5% of the female sex. The age limits with more number of patients were from 3.5 to 11 years. The percentage of patients in a moderate or severe state at the beginning of the study was of 74%. To the first revision they went down to 22%. In second 16%, at third the moderate form represented 8% and the severe form disappeared. The doctor qualified the results of excellent to very good in 88% of the cases and the patient or his relatives in 85%.